Profile: Merck & Co Inc (MRK)
23 Jan 2015
Merck & Co., Inc., incorporated in 1970, is a health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company’s operations are principally managed on a products basis and are comprised of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. The Company also has animal health operations that discover, develop, manufacture and market animal health products, including vaccines, which the Company sells to veterinarians, distributors and animal producers. Additionally, the Company has consumer care operations that develop, manufacture and market over-the-counter, foot care and sun care products, which are sold through wholesale and retail drug, food chain and mass merchandiser outlets, as well as club stores and specialty channels.
The Company’s clinical pipeline includes candidates in multiple disease areas, including atherosclerosis, cancer, cardiovascular diseases, diabetes, infectious diseases, inflammatory/autoimmune diseases, insomnia, neurodegenerative diseases, osteoporosis, respiratory diseases and women’s health. The Company has several candidates under regulatory review in the United States or internationally, such as MK-5348, vorapaxar, is an investigational anti-thrombotic medicine under review by the Food and Drug Administration (FDA) and European Medicines Agency (EMA), V503, the Company’s nine-valent HPV vaccine in development to help protect against certain HPV-related diseases, is under review by the FDA, MK-8962, corifollitropin alfa injection, is an investigational fertility treatment under review by the FDA for controlled ovarian stimulation in women participating in assisted reproductive technology, MK-7243, Grastek (Timothy Grass Pollen Allergen Extract), an investigational Timothy grass pollen allergy immunotherapy tablet (AIT), and MK-3641, Ragwitek (Short Ragweed Pollen Allergen Extract), an investigational ragweed pollen AIT, are both under review by the FDA, MK-4305, suvorexant, is an investigational insomnia medicine in a new class of medicines called orexin receptor antagonists for use in patients with difficulty falling or staying asleep, MK-8616, sugammadex sodium injection, is an investigational agent for the reversal of neuromuscular blockade induced by rocuronium or vecuronium (neuromuscular blocking agents), MK-8109, vintafolide, is an investigational cancer candidate under review by the EMA, MK-7009, vaniprevir, is an investigational, oral twice-daily protease inhibitor for the treatment of chronic hepatitis C virus (HCV) infection under review in Japan, MK-3475, an investigational anti-PD-1 immunotherapy, is currently being evaluated for the treatment of patients with advanced melanoma and other tumor types, MK-3475 clinical development program also includes studies across a broad range of cancer types including: bladder, colorectal, gastric, head and neck, melanoma, non-small cell lung, renal, triple negative breast and hematological malignancies, MK-0822, odanacatib, is an oral, once-weekly investigational treatment for patients with osteoporosis, MK-1293 is an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes and OTX015, which is under development in Phase Ib studies for the treatment of hematological malignancies and advanced solid tumors, among others.
The Company’s pharmaceutical products include therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company provides products in various divisions, such as Primary Care and Women’s Health, Hospital and Specialty, Diversified Brands and Vaccines. The Company’s Primary Care and Women’s Health division offers products of different therapeutic segments, such as Cardiovascular, which include Zetia (ezetimibe) (marketed as Ezetrol outside the United States) and Vytorin (ezetimibe/simvastatin) (marketed as Inegy outside the United States), cholesterol modifying medicines; Diabetes and Obesity, which includes Januvia (sitagliptin) and Janumet (sitagliptin/metformin HCl) for the treatment of type 2 diabetes; Respiratory, which includes Nasonex (mometasone furoate monohydrate), an inhaled nasal corticosteroid for the treatment of nasal allergy symptoms, Singulair (montelukast), a medicine indicated for the chronic treatment of asthma and the relief of symptoms of allergic rhinitis, Dulera Inhalation Aerosol (mometasone furoate/formoterol fumarate dihydrate), a combination medicine for the treatment of asthma and Asmanex Twisthaler (mometasone furoate inhalation powder), an inhaled corticosteroid for first-line maintenance treatment of asthma in patients 4 years of age and older; Women’s Health and Endocrine, which include NuvaRing (etonogestrel/ethinyl estradiol vaginal ring), a vaginal contraceptive ring; Fosamax (alendronate sodium) for the treatment and prevention of osteoporosis, Follistim AQ (follitropin beta injection), a fertility treatment; Implanon (etonogestrel implant), a single-rod subdermal contraceptive implant, Cerazette (desogestrel), a progestin only oral contraceptive, and Other, which include Arcoxia (etoricoxib) for the treatment of arthritis and pain, which the Company markets outside the United States, and Avelox (moxifloxacin), a broad-spectrum fluoroquinolone antibiotic for the treatment of certain respiratory and skin infections, which the Company only markets in the United States.
The Company’s Hospital and Specialty division offers products in the therapeutic categories, such as Immunology, which includes Remicade (infliximab) and Simponi (golimumab) for the treatment of inflammatory diseases, which the Company markets in Europe, Russia and Turkey; Infectious Disease, which includes Isentress (raltegravir), an antiretroviral therapy for use in combination therapy for the treatment of HIV-1 infection, Cancidas (caspofungin acetate), an anti-fungal product, PegIntron (peginterferon alpha-2b), a treatment for chronic hepatitis C, Invanz (ertapenem sodium) for the treatment of certain infections, Victrelis (boceprevir), a treatment for chronic hepatitis C and Noxafil (posaconazole) for the prevention of invasive fungal infections; Oncology, which include Temodar (temozolomide) (marketed as Temodal outside the United States), a treatment for certain types of brain tumors, and Emend (aprepitant) for the prevention of chemotherapy-induced and post-operative nausea and vomiting, and Other, which includes Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution), which the Company markets outside the United States, and Trusopt (dorzolamide hydrochloride ophthalmic solution), ophthalmic products, Bridion (sugammadex sodium injection), a medication for the reversal of certain muscle relaxants used during surgery, and Integrilin (eptifibatide), a treatment for patients with acute coronary syndrome.
The Company’s Diversified Brands include Cozaar (losartan potassium) and Hyzaar (losartan potassium and hydrochlorothiazide), treatments for hypertension; Primaxin (imipenem and cilastatin sodium), an anti-bacterial product; Zocor (simvastatin), a statin for modifying cholesterol; Propecia (finasteride), a product for the treatment of male pattern hair loss; Clarinex (desloratadine), a non-sedating antihistamine; Remeron (mirtazapine), an antidepressant; Claritin Rx (loratadine) for treatment of seasonal outdoor allergies and year-round indoor allergies; Proscar (finasteride), a urology product for the treatment of symptomatic benign prostate enlargement; and Maxalt (rizatriptan benzoate), a product for acute treatment of migraine. The Company’s Vaccines divisions include, Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant), a vaccine to help prevent certain diseases caused by four types of human papillomavirus (HPV); ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live), a pediatric combination vaccine to help protect against measles, mumps, rubella and varicella; M-M-R II (Measles, Mumps and Rubella Virus Vaccine Live), a vaccine to help prevent measles, mumps and rubella; Varivax (Varicella Virus Vaccine Live), a vaccine to help prevent chickenpox (varicella); Zostavax (Zoster Vaccine Live), a vaccine to help prevent shingles (herpes zoster); Pneumovax 23 (pneumococcal vaccine polyvalent), a vaccine to help prevent pneumococcal disease; and RotaTeq (Rotavirus Vaccine, Live Oral, Pentavalent), a vaccine to help protect against rotavirus gastroenteritis in infants and children.
The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The principal products in this segment include: Livestock Products, Poultry Products, Companion Animal Products, and Aquaculture Products. Livestock Products, includes Nuflor antibiotic range for use in cattle and swine; Bovilis/Vista vaccine lines for infectious diseases in cattle; Banamine bovine and swine anti-inflammatory; Estrumate for the treatment of fertility disorders in cattle; Regumate/Matrix fertility management for swine and horses; Resflor combination broad-spectrum antibiotic and non-steroidal anti-inflammatory drug for bovine respiratory disease; Zuprevo for bovine respiratory disease; Zilmax and Revalor to improve production efficiencies in beef cattle; M+Pac swine pneumonia vaccine; and Porcilis vaccine line for infectious diseases in swine.
Poultry Products, such as Nobilis/Innovax, vaccine lines for poultry and Paracox and Coccivac coccidiosis vaccines. Companion Animal Products, includes Nobivac vaccine lines for flexible dog and cat vaccination, Otomax/Mometamax/Posatex ear ointments for acute and chronic otitis, Caninsulin/Vetsulin diabetes mellitus treatment for dogs and cats, Panacur/Safeguard broad-spectrum anthelmintic (de-wormer) for use in many animals and Activyl/Scalibor/Exspot for protecting against bites from fleas, ticks, mosquitoes and sandflies. Aquaculture Products, includes Slice parasiticide for sea lice in salmon, Aquavac/Norvax vaccines against bacterial and viral disease in fish, Compact PD vaccine for salmon and Aquaflor antibiotic for farm-raised fish.
The Consumer Care segment develops, manufactures and markets over-the-counter, foot care and sun care products. Principal products in this segment include Over-the-Counter Products, such as Claritin non-drowsy antihistamines; MiraLAX for relief of occasional constipation, Coricidin HBP decongestant-free cold/flu medicine for people with high blood pressure, Afrin nasal decongestant spray; Zegerid OTC treatment for frequent heartburn and Oxytrol For Women, a treatment for overactive bladder in women; Foot Care products, such as Dr. Scholl’s foot care products, Lotrimin topical antifungal products, and Tinactin topical antifungal products and foot and sneaker odor/wetness products, and Sun Care products, such as Coppertone sun care lotions, sprays and dry oils.
Merck & Co Inc
2000 Galloping Hill Rd
KENILWORTH NJ 07033-1310
Company Web Links
- Europe recommends seven new medicines for approval
- Europe recommends seven new medicines for approval
- Johnson & Johnson's forex warning a sign for rival drugmakers
- Johnson & Johnson's forex warning a sign for rival drugmakers
- Exclusive: Merck funds tests of lower Zilmax doses as seen seeking way to resume sales